Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Summary

To explore the efficacy and safety of pyrotinib combined with docetaxel regimen in the first-line treatment of HER2-positive metastatic breast cancer.

Timeline

Start

2019-03

Primary completion

2019-10

Completion

2020-12

Outcome

Met primary endpoint

paper The pre-specified primary endpoint was met. PMID 38097605 ↗

Publications

• Dai L, Gao T, Guo R, Chen Y, Wang J, Zhou S, Tang Y, Chen D, Huang S. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study. Neoplasia. 2024 Oct;56:101029. doi: 10.1016/j.neo.2024.101029. Epub 2024 Jul 17.
• Zheng Y, Cao WM, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, Li H, Li M, Chen Z, Wang X. Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nat Commun. 2023 Dec 14;14(1):8314. doi: 10.1038/s41467-023-44140-y.

Drugs

Indications